Clinical Trial

A Multicenter Phase II Clinical Study of Neoadjuvant Use of Camrelizumab in Combination With Chemotherapy for Organ Preservation in Esophageal Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a multicenter phase II clinical study to explore the efficacy, safety, and organ preservation feasibility of camrelizumab in combination with chemotherapy for resectable esophageal squamous carcinoma in patients with histologically and pathologically confirmed resectable esophageal squamous carcinoma.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-03-05.
Status change: Not Yet Recruiting → Recruiting 2025-09-28
Trial Details
NCT Number NCT06869226
Lead Sponsor Peking University Cancer Hospital & Institute
Conditions Esophageal Cancer
Enrollment 283 participants
Start Date 2025-04-30
Primary Completion 2029-12-31 (estimated)
Study Completion 2029-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-10-02